New study decodes platelet patterns in TTP drug response
NCT ID NCT05876221
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study analyzed data from 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab. The goal was to understand how platelet counts change during treatment and identify patterns that could help doctors avoid over- or under-treatment. Researchers used mathematical models to describe and predict these platelet responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital of Cologne
Cologne, Germany
Conditions
Explore the condition pages connected to this study.